Browse diseases

…Introduction Pancreatic steatosis is increasingly recognized as a precursor to metabolic dysfunct…

…Background Diagnosing the presence of metastasis of pancreatic cancer is pivotal for patient management and treatment, with contrast-…

…Background The tumor microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC) is heavily infiltrated by inflammatory monocytes (IMs) and tumo…

…Background Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease characterized by early liver metastases. Ch…

…uency, occurring in 28% and 12% of pancreatic cancer (PDAC) and colorectal cancer (CRC), respectively. KRAS G12D-containing peptides are presente…

…Background Pancreatic cancer is traditionally considered an ‘immune cold’ tumor. Although ou…

…eauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A. 2012;109,5934–5941.Abstract 878 Figu…

…demonstrate that tumour cell-autonomous expression of SMPD1, in pancreatic ductal adenocarcinoma (PDAC), is associated with poorer patients’ outcomes. Smpd1 abl…

…adult patients with unresectable locally advanced or metastatic PDAC who initiated first-line NALIRIFOX, mFOLFIRINOX or Gem/NabP acr…

… cell populations in the native tissue and in tumours, that is, pancreatic ductal adenocarcinoma (PDAC) and adenosquamous carcinoma of the pancreas (ASCP).Desig…

… the variation in response to neoadjuvant chemotherapy (NAT) in pancreatic ductal adenocarcinoma (PDAC) remain poorly understood. The gut microbiome has been sh…

…ive to have a scalable, imaging-based method at hand to predict pancreatic cancer before the patient becomes symptomatic and before a lesion beco…